
Rapamycin Improves PROMs in Patients With ME/CFS in Early Trial
Weekly rapamycin improved patient-reported outcome measures (PROMs) in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after 3 months of use.1 These findings, from a phase 1 trial, were presented by Stephanie L. Grach, MD, …